News

New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life

Wednesday, March 22, 2017

BOULDER, Colo., March 22, 2017 (GLOBE NEWSWIRE) -- Biodesix®, Inc. announced today the results of a study demonstrating that the use of the VeriStrat® test for patients with non-small cell lung cancer (NSCLC) directly impacts physician treatment decisions in real-world clinical practice. In the study, use of the VeriStrat test resulted in an 89% decrease in ineffective treatments for patients who tested VeriStrat-Poor. A “decision impact” study demonstrates that a test changes the way patients are treated after test results are known. The decision impact study on VeriStrat was published in Current Medical Research and Opinion.  

Flagship Bioscience: Is PD-L1 Harmonization on the Horizon?

Wednesday, March 22, 2017

Dr. Joseph Krueger, Flagship Bioscience’s Chief Scientific Officer, was recently interviewed by BioCentury about cTA™ harmonization or the potential to use one predictive assay to calibrate the output from multiple assays. Dr. Krueger provided insight about how the cTA™ platform could not only calibrate results across multiple assays, but can optimize cutoff points for patient selection. “The potential to more accurately predict which patients will respond to therapy should allow diagnostics using cTA™ to command a better price, and reimbursement, than existing companion diagnostics that require manual assessment by a pathologist.” 

InDevR Launches Next-Generation Software for the Cypher One™ System

Tuesday, March 21, 2017

BOULDER, Colo.--(BUSINESS WIRE)--InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine manufacturing, today announced the global launch of the next-generation Cypher One™ 3.1 software to further enhance the functionality of the Cypher One™ automated hemagglutination (HA) and hemagglutination inhibition (HAI) interpretation instrument. 

ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update

Tuesday, March 21, 2017

Westminster, CO, March 21, 2017 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended December 31, 2016, and provided a business update.  

Funding round brings in $10.5 million for EndoShape

Tuesday, March 21, 2017

EndoShape has raised $10.5 million in a new round of equity financing, according to an SEC filing posted by the company. 

Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber

Monday, March 20, 2017

Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients 

Bioptix sells $2.3 million in private placement

Monday, March 20, 2017

BOULDER — Bioptix Inc. (Nasdaq: BIOP) sold nearly $2.3 million of its securities in a private placement with accredited investors. 

Loxo Oncology partners with Roche unit on companion Dx development

Monday, March 20, 2017

A partnership has been reached by Loxo Oncology and Roche Holding subsidiary Ventana Medical Systems to create a pan-TRK immunohistochemistry-based companion diagnostic test to determine which patients may respond to Loxo's cancer drug larotrectinib. The test will be developed using Ventana's OptiView DAB detection technology and will be initially marketed as an analytical assay; the companies did not disclose additional terms of the deal. 

Ag biotech firm Front Range Biosciences raises $1.5M

Thursday, March 16, 2017

Front Range Biosciences Inc., a startup agricultural biotech firm based in Lafayette, has raised $1.5 million in funding from five venture-capital firms. 

E.I. Medical Imaging Partners With Denver Zoo to Welcome Baby Giraffe Dobby

Tuesday, March 14, 2017

Loveland, Colorado, March 14, 2017 (Newswire.com) - With all of the excitement around baby giraffes these days, E.I. Medical Imaging (EIMI) is proud to announce that their EVO® ultrasound system was instrumental in determining the pregnancy of Denver Zoo's Kipele. With a complete team effort and some remote viewing technology, the keepers and veterinary staff from Denver Zoo were able to determine and confirm Kipele's pregnancy and prepare for the subsequent birth of baby Dobby.